The triggered arrhythmia was ameliorated by treatment with the CaMKII inhibitor KN-93 or INa,L inhibitor ranolazine, which further confirmed the arrhythmogenic role of the upregulated CaMKII and INa,L induced by ziprasidone. The gene discussed is CAMK2G; the disease is Arrhythmia.